Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Nucleoprotein Is Required for Lymphocytic Choriomeningitis Virus-Based Vaccine Vector Immunogenicity.

Literature DB >> 26355095

The Nucleoprotein Is Required for Lymphocytic Choriomeningitis Virus-Based Vaccine Vector Immunogenicity.

Stephanie Darbre¹, Susan Johnson¹, Sandra Kallert², Paul-Henri Lambert¹, Claire-Anne Siegrist¹, Daniel D Pinschewer³.

Abstract

Recombinant glycoprotein-deficient lymphocytic choriomeningitis virus-based vaccine vectors (rLCMV/ΔGP) are potent CD8(+) T cell inducers. To investigate the underlying molecular requirements, we generated a nucleoprotein-deficient vector counterpart (rLCMV/ΔNP). NP but not GP is a minimal trans-acting factor for viral transcription and genome replication. We found that, unlike rLCMV/ΔGP, rLCMV/ΔNP failed to elicit detectable CD8(+) T cell responses unless NP was trans complemented in a transgenic host. Hence, NP-dependent intracellular gene expression is essential for LCMV vector immunogenicity.

Entities: Chemical

Mesh：

Substances：

Year: 2015 PMID： 26355095 PMCID： PMC4645649 DOI： 10.1128/JVI.01613-15

Source DB: PubMed Journal: J Virol ISSN： 0022-538X Impact factor: 5.103

17 in total

1. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs.

Authors: K J Lee; I S Novella; M N Teng; M B Oldstone; J C de La Torre
Journal: J Virol Date: 2000-04 Impact factor: 5.103

2. Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles.

Authors: Ki Jeong Lee; Mar Perez; Daniel D Pinschewer; Juan Carlos de la Torre
Journal: J Virol Date: 2002-06 Impact factor: 5.103

3. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates.

Authors: Lukas Flatz; Cheng Cheng; Lingshu Wang; Kathryn E Foulds; Sung-Youl Ko; Wing-Pui Kong; Rahul Roychoudhuri; Wei Shi; Saran Bao; John-Paul Todd; Mohammed Asmal; Ling Shen; Mitzi Donaldson; Stephen D Schmidt; Jason G D Gall; Daniel D Pinschewer; Norman L Letvin; Srinivas Rao; John R Mascola; Mario Roederer; Gary J Nabel
Journal: J Virol Date: 2012-05-16 Impact factor: 5.103

4. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Authors: Kylie M Quinn; Daniel E Zak; Andreia Costa; Ayako Yamamoto; Kathrin Kastenmuller; Brenna J Hill; Geoffrey M Lynn; Patricia A Darrah; Ross W B Lindsay; Lingshu Wang; Cheng Cheng; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Emma Gostick; David A Price; Jason G D Gall; Mario Roederer; Alan Aderem; Robert A Seder
Journal: J Clin Invest Date: 2015-02-02 Impact factor: 14.808

5. Characterization of CD8+ T cell function and immunodominance generated with an H2O2-inactivated whole-virus vaccine.

Authors: Joshua M Walker; Hans-Peter Raué; Mark K Slifka
Journal: J Virol Date: 2012-10-10 Impact factor: 5.103

6. Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation.

Authors: Rahul Roychoudhuri; Francois Lefebvre; Mitsuo Honda; Li Pan; Yun Ji; Christopher A Klebanoff; Carmen N Nichols; Slim Fourati; Ahmed N Hegazy; Jean-Philippe Goulet; Luca Gattinoni; Gary J Nabel; Michel Gilliet; Mark Cameron; Nicholas P Restifo; Rafick P Sékaly; Lukas Flatz
Journal: Vaccine Date: 2014-11-01 Impact factor: 3.641

7. Development of a new hydrogen peroxide–based vaccine platform.

Authors: Ian J Amanna; Hans-Peter Raué; Mark K Slifka
Journal: Nat Med Date: 2012-06 Impact factor: 53.440

8. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.

Authors: Lukas Flatz; Ahmed N Hegazy; Andreas Bergthaler; Admar Verschoor; Christina Claus; Marylise Fernandez; Luca Gattinoni; Susan Johnson; Florian Kreppel; Stefan Kochanek; Maries van den Broek; Andreas Radbruch; Frédéric Lévy; Paul-Henri Lambert; Claire-Anne Siegrist; Nicholas P Restifo; Max Löhning; Adrian F Ochsenbein; Gary J Nabel; Daniel D Pinschewer
Journal: Nat Med Date: 2010-02-07 Impact factor: 53.440

9. A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.

Authors: Amelia K Pinto; Justin M Richner; Elizabeth A Poore; Pradnya P Patil; Ian J Amanna; Mark K Slifka; Michael S Diamond
Journal: J Virol Date: 2012-12-05 Impact factor: 5.103

10. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest.

Authors: Sebastien F Emonet; Lucile Garidou; Dorian B McGavern; Juan C de la Torre
Journal: Proc Natl Acad Sci U S A Date: 2009-02-10 Impact factor: 11.205

4 in total

1. Replicating viral vector platform exploits alarmin signals for potent CD8⁺ T cell-mediated tumour immunotherapy.

Authors: Sandra M Kallert; Stephanie Darbre; Weldy V Bonilla; Mario Kreutzfeldt; Nicolas Page; Philipp Müller; Matthias Kreuzaler; Min Lu; Stéphanie Favre; Florian Kreppel; Max Löhning; Sanjiv A Luther; Alfred Zippelius; Doron Merkler; Daniel D Pinschewer
Journal: Nat Commun Date: 2017-05-26 Impact factor: 14.919